Perhexiline

Research use only, not for human use.

Perhexiline is a prophylactic antianginal agent that inhibits carnitine palmitoyltransferase (CPT1/CPT2).

Perhexiline is a prophylactic antianginal agent that inhibits carnitine palmitoyltransferase (CPT1/CPT2); promotes HER3 ablation through receptor internalization and inhibits tumor growth; activates KLF14 and reduces atherosclerosis by modulating ApoA-I production.Hypertension Phase 2 Clinical.

Perhexiline (5-25 μM, 2-6 h) reduces cell viability in HepG2 cells.Perhexiline (5-25 μM, 2-6 h) reduces cellular ATP content and Lactate dehydrogenase (LDH) release in HepG2 cells.Perhexiline (20 μM, 2 h) activates caspase 3/7 in HepG2 cells.Perhexiline (5-25 μM, 4 h) causes mitochondrial dys function in HepG2 cells.Perhexiline (5 μM, 48 h) selectively induces massive apoptosis in CLL cells (high expression of CPT). Cell Viability Assay Cell Line:HepG2 cells Concentration:5, 10, 15, 25 μM Incubation Time:2, 4, 6 h Result:Induced time- and concentration-dependent cytotoxicity in hepatic cells.Western Blot Analysis Cell Line:HepG2 cells Concentration:5, 10, 15, 25 μM Incubation Time:2 h Result:Reduced Bcl-2 and Mcl-1 level, and increased Bad level.

Perhexiline (200 mg/kg, p.o., daily for 8 weeks) reduces peripheral neural function in female DA rats.Perhexiline (80 mg/kg, oral gavage, for 3 days) demonstrates anti-tumor activity in glioblastoma mouse model. Animal Model:Orthotopic glioblastoma mouse model Dosage:80 mg/kg Administration:Oral gavage, for 3 days. Result:Reduces tumor size (MR imaging) and improves in overall survival.

——

Others

Other Targets

Other Targets

Cardiovascular Disease

Hypertension

6621-47-2

277.496

C19H35N

>98% (HPLC)

——

C1CCC(CC1)C(CC2CCCCN2)C3CCCCC3

2-(2,2-dicyclohexylethyl)-piperidine

(-20℃)

With Ice Pack

≥ 2 years